CompletedNCT00649064
A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs
Medication studyAges 18–65Taiwan
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Changhua and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateDecember 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 46
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Taiwan
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00649064
- Official title
Show the full official title
A Multi-Center Study To Examine The Clinical Effects Of Cross Titration Of Antipsychotics With Ziprasidone In Subjects With Schizophrenia Or Schizoaffective Disorder
Get this study by email
Recruitment & locations
CompletedChanghua · Tainan · Taipei
Questions about this study
Who is behind this study?
The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Did this study involve medication?
Yes. The study involved medication, including Ziprasidone.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
